Topics in Anti-Cancer Research

Volume 5


Atta-ur-Rahman / Khurshid Zaman

DOI: 10.2174/97816810833391160501
eISBN: 978-1-68108-333-9, 2016
ISBN: 978-1-68108-334-6
ISSN: 2468-5860 (Print)
ISSN: 2213-3585 (Online)

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

The fifth volume of this series entitled “Topics in Anti-Cancer Research” presents an overview of recent developments in the field of ...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII

- Pp. 3-42 (40)

Mam Y. Mboge, Robert McKenna and Susan C. Frost


The microenvironment within a solid tumor is heterogeneous with regions being both acidic and hypoxic. As a result of this, cancer cells upregulate genes that allow survival in such environments. Some of these genes are pH regulatory factors, including carbonic anhydrase IX (CA IX) and in some cases XII (CA XII). CA IX helps to maintain normal cytoplasmic pH (pHi) while simultaneously contributing to the extracellular pH (pHe). CA XII is also thought to be responsible for stabilizing pHe at physiological conditions. Extracellular acidification of the tumor microenvironment promotes local invasion and metastasis while decreasing the effectiveness of adjuvant therapies, thus contributing to poor cancer clinical outcomes. In this review, we describe the properties of CA IX and CA XII that substantiate their potential use as anticancer targets. We also discuss the current status of CA isoform-selective inhibitor development and patents of CA IX/XII targeted inhibitors that show potential for treating aggressive tumors. Some of the recently published patents discussed include sulfonamide-based small molecule inhibitors including derivatives of boron cluster compounds; metal complexes of poly(carboxyl)amine-containing ligands; nitroimidazole-, ureidosulfonamide-, and coumarin-based compounds; as well as G250 and A610 monoclonal antibodies for cancer treatment.

Purchase Chapter  Book Details


Webmaster Contact: Copyright © 2018 Bentham Science